搜索筛选:
搜索耗时1.3312秒,为你在为你在102,285,761篇论文里面共找到 8 篇相符的论文内容
发布年度:
Phase Ⅱ study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric canc
[期刊论文] 作者：Hiroshi Imamura,Masataka Ikeda,
来源：世界胃肠病学杂志：英文版（电子版） 年份：2006
...
[期刊论文] 作者：Hiroshi Imamura Toshihiro Kona,
来源：世界胃肠病学杂志：英文版（电子版） 年份：2007
经皮的内视镜的胃造口术(木钉) 通常与严肃的复杂并发症的低率被认为安全。然而，进十二指肠的木钉试管的脱臼能导致严肃的复杂并发症。没有放射线学的证实，有喂有时在她的家庭......
[期刊论文] 作者：Hiroshi Imamura,Toshihiro Konagaya,Takashi Hashimoto,Kunio Kasugai,
来源：世界胃肠病学杂志（英文版） 年份：2007
Percutaneous endoscopic gastrostomy (PEG) is generally considered safe with a low rate of serious complications. However, dislocation of the PEG-tube into the d...
[会议论文] 作者：Kazuyuki Okada,Hiroshi Imamura,Ryohei Kawabata,Yukinori Kurokawa,Taroh Satoh,
来源：第十二届国际胃癌学术会议 年份：2017
...
[期刊论文] 作者：Yoshinori Inagaki,Norihiro Kokudo,Yasuji Seyama,Munehiro Nakata,Hiroshi Imamura,Keiji Sano,Yasuhiko Sugawara,
来源：World Journal of Gastroenterology 年份：2005
AIM: To assess histochemical expression of KL-6 and its clinicopathological significance in carcinoma of the ampulla of Vater. METHODS: Ampullary carcinoma tiss...
[期刊论文] 作者：Hironori Shigeoka,Haruhiko Imamoto,Yasumasa Nishimura,Taro Shimono,Hiroshi Furukawa,Hiroshi Imamura,Takushi,
来源：World Journal of Gastrointestinal Oncology 年份：2010
This report presents a case of highly advanced gastric cancer that achieved a histologically complete response (CR) to preoperative chemoradiotherapy with S-1 p...
[期刊论文] 作者：Wei Tang,Yoshinori Inagaki,Norihiro Kokudo,Qian Guo,Yasuji Seyama,Munehiro Nakata,Hiroshi Imamura,Keiji,
来源：世界胃肠病学杂志（英文版） 年份：2005
AIM: To assess histochemical expression of KL-6 and its clinicopathological significance in carcinoma of the ampulla of Vater.METHODS: Ampullary carcinoma tissu...
Phase Ⅱ study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric canc
[期刊论文] 作者：Hiroshi Imamura,Masataka Ikeda,Hiroshi Furukawa,Toshimasa Tsujinaka,Kazumasa Fujitani,Kenji Kobayashi,
来源：World Journal of Gastroenterology 年份：2006
AIM: To test protracted irinotecan infusion plus a low-dose cisplatin in this Phase Ⅱ trial to decrease its toxic-ity. METHODS: The eligibility criteria were:...
相关搜索：
